Domain > ir.anixa.com

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2020-07-16	54.227.147.28 (ClassC)
2021-09-10	3.221.176.71 (ClassC)
2021-11-12	18.157.192.248 (ClassC)
2023-12-19	54.225.202.48 (ClassC)
2024-12-10	34.232.252.169 (ClassC)
2025-09-14	35.171.180.101 (ClassC)
2026-01-30	52.53.59.161 (ClassC)

Port 443

HTTP/1.1 200 OKDate: Fri, 30 Jan 2026 01:46:59 GMTServer: ApacheVary: Accept-EncodingTransfer-Encoding: chunkedContent-Type: text/html; charsetUTF-8

!DOCTYPE html>!--if lt IE 7>      html classno-js lt-ie9 lt-ie8 lt-ie7 langen> !endif-->!--if IE 7>         html classno-js lt-ie9 lt-ie8 langen> !endif-->!--if IE 8>         html classno-js lt-ie9 langen> !endif-->!--if gt IE 8>!--> html classno-js langen> !--!endif-->     head>base hrefhttps://www.anixa.com />link hrefhttps://ir.anixa.com/stylesheets/ir.stockpr.css relstylesheet typetext/css mediascreen />link relalternate typeapplication/rss+xml titleAnixa Biosciences, Inc.(ANIX) - Recent News hrefhttps://ir.anixa.com/rss />script typetext/javascript srchttps://ir.anixa.com/javascripts/ir.js>/script>        meta charsetutf-8>        title>Investors :: Anixa Biosciences, Inc. (ANIX)/title>                        meta propertyog:site_name contentAnixa Biosciences, Inc. (ANIX)>        meta propertyog:title contentInvestors :: Anixa Biosciences, Inc. (ANIX)>        meta propertyog:type contentwebsite>        meta propertyog:image contenthttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/logo.png>        meta propertyog:url contenthttp://ir.anixa.com/>        meta nameviewport contentinitial-scale1.0, widthdevice-width>        link relstylesheet hrefhttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/css/style.css>        link relstylesheet hrefhttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/css/print.css mediaprint>              link relapple-touch-icon sizes180x180 hrefhttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/favicons/apple-touch-icon.png>    link relicon typeimage/png sizes32x32 hrefhttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/favicons/favicon-32x32.png>    link relicon typeimage/png sizes16x16 hrefhttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/favicons/favicon-16x16.png>    link relmanifest hrefhttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/favicons/site.webmanifest>    link relmask-icon hrefhttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/favicons/safari-pinned-tab.svg color#5bbad5>    meta namemsapplication-TileColor content#da532c>    meta nametheme-color content#ffffff>        !-- Google Tag Manager -->script>(function(w,d,s,l,i){wlwl||;wl.push({gtm.start:new Date().getTime(),event:gtm.js});var fd.getElementsByTagName(s)0,jd.createElement(s),dll!dataLayer?&l+l:;j.asynctrue;j.srchttps://www.googletagmanager.com/gtm.js?id+i+dl;f.parentNode.insertBefore(j,f);})(window,document,script,dataLayer,GTM-M9PW9BWV);/script>!-- End Google Tag Manager -->        !-- Google tag (gtag.js) -->script async srchttps://www.googletagmanager.com/gtag/js?idG-6K2MHEKZ7P>/script>script>  window.dataLayer  window.dataLayer || ;  function gtag(){dataLayer.push(arguments);}  gtag(js, new Date());  gtag(config, G-6K2MHEKZ7P);/script>                            /head>body>    div classgeneral-wrapper>    !-- Google Tag Manager (noscript) -->noscript>iframe srchttps://www.googletagmanager.com/ns.html?idGTM-M9PW9BWVheight0 width0 styledisplay:none;visibility:hidden>/iframe>/noscript>!-- End Google Tag Manager (noscript) -->header>    div classcontainer>        h1 classlogo>            a href/>                img srchttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/header-logo.png altAnixa Biosciences, Inc.>           /a>        /h1>        a classvisible-xs visible-sm mobile-nav-trigger idshowRight>            div classmeat>/div>            div classmeat>/div>            div classmeat>/div>        /a>        div classheader-nav clearfix>            div classtop-bar>                div classtop-links>                    a classeqicon eqicon-social-01-facebook hrefhttps://www.facebook.com/anixabiosciences/ target_blank altfacebook >/a>                    a hrefhttps://twitter.com/anixabio target_blank>img srchttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/twitter_x_rounded.svg alttwitter logo>/a>                    a classeqicon eqicon-social-01-linkedin hrefhttps://www.linkedin.com/company/anixabiosciences/ target_blank altLinkedIn>/a>                    a classeqicon eqicon-social-01-youtube hrefhttps://www.youtube.com/channel/UChbBxir26JYqSTgCNcyDmuQ/videos target_blank altYouTube>/a>                    div classsymbol>a hrefhttps://ir.anixa.com>span classvalue>Nasdaq: span classhighlight>ANIX/span>/span>/a>/div>                /div>            /div>            div classhome-nav>                nav classcbp-spmenu cbp-spmenu-vertical cbp-spmenu-right main-nav idmobile-nav>                    ul classmain-menu header-nav>    li classsr-only>a href/>Home/a>/li>            li classhas-children  data-submenu-idsubmenu-about>    a   href/about>About/a>            ul idsubmenu-about>                                        li >a  href/about/overview>Overview/a>                                    /li>                                        li >a  href/about/management-team>Management Team/a>                                    /li>                                        li >a  href/about/board-of-directors>Board of Directors/a>                                    /li>                                        li >a  href/about/scientific-advisors>Scientific Advisors/a>                                    /li>                                        li >a  href/about/breast-cancer-clinical-advisory-board>Breast Cancer Clinical Advisory Board/a>                                    /li>                                        li >a  href/about/cancer-business-advisory-board>Cancer Business Advisory Board/a>                                    /li>                    /ul>    /li>            li classhas-children  data-submenu-idsubmenu-technologies>    a   href/technologies>Technologies/a>            ul idsubmenu-technologies>                                        li classhas-sub-subpages>a  href/technologies/car-t>CAR-T/a>                                            ul classsub-sub-pages>                                                    li>a  href/technologies/car-t/introduction>Introduction/a>                                                    li>a  href/technologies/car-t/markets>Markets/a>                                                    li>a  href/technologies/car-t/science>Science/a>                                                    li>a  href/technologies/car-t/collaborators>Collaborators/a>                                                /ul>                                    /li>                                        li classhas-sub-subpages>a  href/technologies/cancer-vaccines>Cancer Vaccines/a>                                            ul classsub-sub-pages>                                                    li>a  href/technologies/cancer-vaccines/introduction>Introduction/a>                                                    li>a  href/technologies/cancer-vaccines/markets>Markets/a>                                                    li>a  href/technologies/cancer-vaccines/science>Science/a>                                                    li>a  href/technologies/cancer-vaccines/collaborators>Collaborators/a>                                                    li>a  href/technologies/cancer-vaccines/breast-cancer-clinical-advisory-board>Breast Cancer Clinical Advisory Board/a>                                                /ul>                                    /li>                    /ul>    /li>            li class  data-submenu-idsubmenu-pipeline>    a   href/pipeline>Pipeline/a>    /li>            li classhas-children active data-submenu-idsubmenu-investors>    a   href/investors>Investors/a>            ul idsubmenu-investors>                                        li >a  href/investors/_>Overview/a>                                    /li>                                        li >a  href/investors/press-releases>News Releases/a>                                    /li>                                        li >a  href/investors/invest-in-the-future-of-cancer-immunotherapy-womens-health>The Future of Cancer Immunotherapy & Women’s Health/a>                                    /li>                                        li classhas-sub-subpages>a  href/investors/events-presentations>Events & Presentations/a>                                            ul classsub-sub-pages>                                                    li>a  href/investors/events-presentations/events>Events/a>                                                    li>a  href/investors/events-presentations/corporate-presentation>Corporate Presentation/a>                                                /ul>                                    /li>                                        li classhas-sub-subpages>a  href/investors/stock-information>Stock Information/a>                                            ul classsub-sub-pages>                                                    li>a  href/investors/stock-information/quote>Quote/a>                                                    li>a  href/investors/stock-information/charts>Charts/a>                                                    li>a  href/investors/stock-information/historical-data>Historical Data/a>                                                    li>a  href/investors/stock-information/analyst-coverage>Analyst Coverage/a>                                                /ul>                                    /li>                                        li classhas-sub-subpages>a  href/investors/sec-filings>SEC Filings/a>                                            ul classsub-sub-pages>                                                    li>a  href/investors/sec-filings/sec-filings>SEC Filings/a>                                                /ul>                                    /li>                                        li classhas-sub-subpages>a  href/investors/financial-reports>Financial Reports/a>                                            ul classsub-sub-pages>                                                    li>a  href/investors/financial-reports/annual-reports>Annual Reports/a>                                                    li>a  href/investors/financial-reports/quarterly-reports>Quarterly Reports/a>                                                /ul>                                    /li>                                        li classhas-sub-subpages>a  href/investors/corporate-governance>Corporate Governance/a>                                            ul classsub-sub-pages>                                                    li>a  href/investors/corporate-governance/governance-docs>Governance Documents/a>                                                    li>a  href/investors/corporate-governance/committee-charters>Committee Charters/a>                                                /ul>                                    /li>                    /ul>    /li>            li classhas-children  data-submenu-idsubmenu-news>    a   href/news>News/a>            ul idsubmenu-news>                                        li >a  href/news/press-releases>Press Releases/a>                                    /li>                                        li >a  href/news/anixa-in-the-news>Anixa In The News/a>                                    /li>                                        li >a  href/news/publications>Publications/a>                                    /li>                                        li >a target_blank href/news/youtube-channel>YouTube Channel/a>                                    /li>                    /ul>    /li>            li class  data-submenu-idsubmenu-contact>    a   href/contact>Contact Us/a>    /li>    /ul>                /nav>            /div>        /div>    /div>/header>div classpage-hero page-hero  background page-hero-overlay   stylebackground-image: url(https://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/db/38/582/image.jpg)>    div classcontainer>    	div classvertical-align>    		div classwrapper text dark center>    			h1>Investors/h1>    			    		/div>    	/div>    /div>    div classblend-bar>/div>/div>	div classsub-navigation ir-navigation>    	div classcontainer>a classvisible-xs visible-sm mobile-sub-nav-trigger collapsed data-togglecollapse data-target#sub-navigation>    div classtrigger-container>		div classmeat>/div>  		div classmeat>/div>  		div classmeat>/div>  	/div>	Investors/a>    a href/investors>h3>Investors/h3>/a>nav classcollapse sb-nav clearfix  idsub-navigation>    ul>                            li classactive >a href/investors/_ >Overview/a>            	    		/li>    	                    li class >a href/investors/press-releases >News Releases/a>            	    		/li>    	                    li class >a href/investors/invest-in-the-future-of-cancer-immunotherapy-womens-health >The Future of Cancer Immunotherapy & Women’s Health/a>            	    		/li>    	                    li class  has-children dropdown>a href/investors/events-presentations >Events & Presentations/a>            	    				ul classdropdown-menu>																					li>a href/investors/events-presentations/events >Events/a>                                                    /li>																					li>a href/investors/events-presentations/corporate-presentation >Corporate Presentation/a>                                                    /li>					    				/ul>    			    		/li>    	                    li class  has-children dropdown>a href/investors/stock-information >Stock Info/a>            	    				ul classdropdown-menu>																					li>a href/investors/stock-information/quote >Quote/a>                                                    /li>																					li>a href/investors/stock-information/charts >Charts/a>                                                    /li>																					li>a href/investors/stock-information/historical-data >Historical Data/a>                                                    /li>																					li>a href/investors/stock-information/analyst-coverage >Analyst Coverage/a>                                                    /li>					    				/ul>    			    		/li>    	                    li class  has-children dropdown>a href/investors/sec-filings >SEC Filings/a>            	    				ul classdropdown-menu>															    				/ul>    			    		/li>    	                    li class  has-children dropdown>a href/investors/financial-reports >Financial Reports/a>            	    				ul classdropdown-menu>																					li>a href/investors/financial-reports/annual-reports >Annual Reports/a>                                                    /li>																					li>a href/investors/financial-reports/quarterly-reports >Quarterly Reports/a>                                                    /li>					    				/ul>    			    		/li>    	                    li class  has-children dropdown>a href/investors/corporate-governance > Governance/a>            	    				ul classdropdown-menu>																					li>a href/investors/corporate-governance/governance-docs >Governance Documents/a>                                                    /li>																					li>a href/investors/corporate-governance/committee-charters >Committee Charters/a>                                                    /li>					    				/ul>    			    		/li>    			    	     li classir-sidebar has-children ir-tools hidden-xs hidden-sm>            a hrefjavascript:void(0); data-toggledropdown>Investor Resources/a>            ul classdropdown-menu>    li>a hrefhttps://ir.anixa.com/investor-faqs classsheet>Investor FAQs/a>/li>    li>a hrefhttps://ir.anixa.com/email-alerts classemail>Email Alerts/a>/li>            li>a hrefhttps://content.equisolve.net/anixa/db/73/1301/fact_sheet/ANIX_Fact+Sheet_1.12.26.pdf target_blank titleFact Sheet classsheet>Fact Sheet/a>/li>        li>a hrefhttps://ir.anixa.com/contacts classcontacts>Contact IR/a>/li>    li>a hrefhttps://ir.anixa.com/rss classrss target_blank>RSS News Feed/a>/li>/ul>        /li>        /ul>    /nav>/div>/div>        div classgeneral-content idcontent>                 div classcontainer>                div classrow>                                                    div classcol-md-8 col-md-offset-2>                        div classir-content full-width text>                                div classrow>        div classcol-md-12>            div classbox js-same-height bottom-btn latest-news>    div classheader>        div classpull-right share-icons>    		a hrefhttps://ir.anixa.com/email-alerts>				span classeqicon-social-01-email>/span>			/a>			a hrefhttps://ir.anixa.com/news/rss target_blank>				span classeqicon-social-01-rss>/span>			/a>		/div>		a hrefhttps://ir.anixa.com/press-releases/>h2 classicon-bg-news>Latest News/h2>/a>	/div>	article classtext>    		div classsingle-new>			h3>a hrefhttps://ir.anixa.com/press-releases/detail/1109/anixa-biosciences-receives-notice-of-allowance-from-mexican>Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology/a>/h3>			div classdate>time datetime2026-01-27 08:30:00>Jan 27, 2026/time>/div>		/div>		a hrefhttps://ir.anixa.com/press-releases/detail/1109/anixa-biosciences-receives-notice-of-allowance-from-mexican classbtn>Read Press Release/a>    	/article>/div>        /div>       /div>      div classrow same-height-row>    div classcol-md-12>      div classbox quarterly-results divided height>        div classheader>          h2 classicon-bg-results>Latest Financial Results/h2>        /div>        div classtext>          div classtext>  div classrow>          div classcol-sm-4 results-info>        h3>2025/h3>                    p>Year End Results/p>                div classdate>Ended Oct 31, 2025/div>                              /div>        div classcol-sm-8>           div classresult-line>  div classpull-right>    a hrefhttps://ir.anixa.com/sec-filings/content/0001493152-26-001845/0001493152-26-001845.pdf title10-K classlink target_blank>span classeqicon-PDF>/span> PDF/a>    a hrefhttps://ir.anixa.com/sec-filings/content/0001493152-26-001845/form10-k.htm title10-K Filing Viewer classlink fancybox fancybox.iframe>span classeqicon-HTML>/span> HTML/a>  /div>  a hrefhttps://ir.anixa.com/sec-filings/content/0001493152-26-001845/form10-k.htm title10-K Filing Viewer classfancybox fancybox.iframe>10-K span classsr-only>Filing/span>/a>/div>!-- Financials Page -->div classresult-line>  div classpull-right>    a hrefhttps://ir.anixa.com/financials titleQ4 2025 Financials classlink>      span classeqicon-HTML>/span> HTML    /a>  /div>  a hrefhttps://ir.anixa.com/financials titleQ4 2025 Financials>Financials/a>/div>!-- XBRL -->div classresult-line>  div classpull-right>    a hrefhttps://ir.anixa.com/sec-filings/content/0001493152-26-001845/0001493152-26-001845-xbrl.zip titleDownload Raw XBRL Files classlink target_blank>span classeqicon-ZIP>/span> ZIP/a>    a hrefhttps://ir.anixa.com/sec-filings/content/0001493152-26-001845/Financial_Report.xls titleXBRL Spreadsheet classlink target_blank>span classeqicon-PDF>/span> XLS/a>    a hrefhttps://ir.anixa.com/sec-filings/xbrl_doc_only/11115 titleXBRL Viewer classlink fancybox fancybox.iframe>span classeqicon-HTML>/span> HTML/a>  /div>  a hrefhttps://ir.anixa.com/sec-filings/xbrl_doc_only/11115 titleXBRL Viewer classfancybox fancybox.iframe>XBRL/a>/div>    /div>  /div>/div>         /div>      /div>    /div>      /div>div classbox stock-info ir-quote-box data-symbolANIX>    div classheader>        h2 classicon-bg-stock>Stock Information/h2>        time>/time>        div classclear>/div>    /div>    div classtext>    	div classrow js-same-height-row>			div class col-md-4 col-sm-12 col-xs-12 symbol stock-section>				div classstock-box js-same-height>					h3 classvalue-title>Symbol/h3>					span classsymbol> ANIX/span>				/div>			/div>			div classcol-md-4 col-sm-12 col-xs-12 price stock-section>				div classstock-box price js-same-height>					h3 classvalue-title>Price/h3>					span classvalue>span classloader>/span>/span>				/div>			/div>			div classcol-md-4 col-sm-12 col-xs-12 change stock-section>				div classstock-box change js-same-height>					h3 classvalue-title>Change/h3>					span>span classeqicon-change-02>/span> span classvalue>span classnumber>span classloader>/span>/span> span classpercent>/span>/span>/span>				/div>			/div>		/div>		div classrow ir-stock-overview-row-bottom>            div classcol-md-4 col-sm-12 col-xs-12 stock-section>            				div classstock-box volume>					h3 classvalue-title>Volume/h3>    				span classvalue>span classloader>/span>/span>				/div>			/div>    		div classcol-md-4 col-sm-12 col-xs-12 stock-section>            	div classstock-box week-range>            		h3 classvalue-title>52 week Low/High/h3>            		p classvalue>span classloader>/span>/p>            	/div> !-- .stock-box -->            /div> !-- .stock-section -->                	div classcol-md-4 col-sm-12 col-xs-12 stock-section>        		div classstock-box day-range>            		h3 classvalue-title>Day Low/High/h3>            		p classvalue>span classloader>/span>/p>        		/div> !-- .stock-box -->        	/div> !-- .stock-section -->        /div>	/div>/div>div classbox company-overview>    div classheader>        h2 classicon-bg-overview>Company Overview/h2>	/div>	div classtext>        p>Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixas therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Companys vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against retired proteins that have been found to be expressed in certain forms of cancer. Anixas unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization./p>			/div>/div>                        /div>                    /div>                                                            /div>            /div>!-- //container-->        div classsubscribe>    div classcontainer>        h2>Sign up for email Updates/h2>        p>Be The First to Receive Breaking News/p>        a href/email-alerts classbtn>Sign Up Now/a>    /div>/div>div classprefooter>    div classcontainer>        div classrow>            div classcol-sm-7>                div classlogo-social clearfix>    figure>img srchttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/footer-logo.png altLogo Itus>/figure>    div classfooter-social-links clearfix>        a classeqicon eqicon-social-01-facebook hrefhttps://www.facebook.com/anixabiosciences/ target_blank altfacebook >/a>        a hrefhttps://twitter.com/anixabio target_blank>img srchttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/twitter_x_rounded.svg alttwitter logo>/a>        a classeqicon eqicon-social-01-linkedin hrefhttps://www.linkedin.com/company/anixabiosciences/ target_blank altLinkedIn>/a>        a classeqicon eqicon-social-01-youtube hrefhttps://www.youtube.com/channel/UChbBxir26JYqSTgCNcyDmuQ/videos target_blank altYouTube>/a>    /div>/div>                                div classhome-news>    h4>Latest News & Events/h4>    div classnews media>        div classmedia-body>                                    div classnews-text>                time datetime2026-01-27 08:30:00>Jan 27, 2026/time>                p>Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology/p>                a hrefhttps://ir.anixa.com/press-releases/detail/1109/anixa-biosciences-receives-notice-of-allowance-from-mexican>Read More.../a>            /div>                          div classnews-text>                time datetime2025-12-15 08:45:00>Dec 15, 2025/time>                p>Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic/p>                a hrefhttps://ir.anixa.com/press-releases/detail/1108/anixa-biosciences-announces-transfer-of-ind-for-breast>Read More.../a>            /div>                          div classnews-text>                time datetime2025-12-11 18:02:00>Dec 11, 2025/time>                p>Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants/p>                a hrefhttps://ir.anixa.com/press-releases/detail/1107/anixa-biosciences-announces-positive-phase-1-data-for>Read More.../a>            /div>                      /div>    /div>/div>            /div>            div classcol-sm-5>                                            /div>        /div>    /div>/div>!-- Pre Footer -->footer>    div classcontainer>        div classcopyright>           Copyrights © 2026 a href/>Anixa Biosciences, Inc./a>. All Rights Reserved.        /div>        div classfooter-links>            a classeqicon eqicon-social-01-facebook hrefhttps://www.facebook.com/anixabiosciences/ target_blank altfacebook >/a>            a hrefhttps://twitter.com/anixabio target_blank>img srchttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/images/twitter_x_rounded.svg alttwitter logo>/a>            a classeqicon eqicon-social-01-linkedin hrefhttps://www.linkedin.com/company/anixabiosciences/ target_blank altLinkedIn>/a>            a classeqicon eqicon-social-01-youtube hrefhttps://www.youtube.com/channel/UChbBxir26JYqSTgCNcyDmuQ/videos target_blank altYouTube>/a>                       a href/privacy-policy>Privacy Policy/a>            a href/>Terms of Use/a>            a href/disclaimer>Disclaimer/a>            a href/sitemap>Sitemap/a>            /div>        /div>/footer>!-- Footer -->!-- for hCaptcha (Old Sites) -->script idcompanyVars typeapplication/json>{    hCaptchaSiteKey: 778a5748-d323-4b73-a06c-9625642de8bc}/script>script srchttps://d1io3yog0oux5.cloudfront.net/_77b862704c15c309de00aae6136d1fb0/anixa/files/theme/js/_js/all.js>/script>script typetext/javascript>  var jqxhr  jq.get( https://www.anixa.com/api/v1/quote, function(data) {    populateQuoteBox(data);  });/script>script>     var $buoop  {    	c: 2    };        function $buo_f() {    	var e  document.createElement(script);    	e.src  //browser-update.org/update.min.js;    	document.body.appendChild(e);    }    try {    	document.addEventListener(DOMContentLoaded, $buo_f, false)    } catch (e) {    	window.attachEvent(onload, $buo_f)    }/script>        /div>!-- //general-wrapper-->        /div>    /body>/html>

Subdomains

Date	Domain	IP
autodiscover.anixa.com	2025-10-19	52.96.214.56
ir.anixa.com	2026-01-30	52.53.59.161

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > ir.anixa.com

Is this malicious?

DNS Resolutions

Port 443

Subdomains